Last updated: 2026-09-06 09:30:01. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
HCW Biologics Inc. (HCWB) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.88, with a market capitalization of $6.16M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.50 to $36.65. This page covers its latest market performance, valuation, price trends and company information.
$6.16M | |
$2.81 | |
$1,866.00 | |
$1.50 | |
$2.87 | |
29.78K | |
-- | |
-- | |
$36.65 | |
$1.50 | |
-- | |
-- |
HCW Biologics Inc. (HCWB) last closed at $2.87 as of 2026-09-04 23:56:00, unchanged from the previous close of $2.87.
During the latest regular trading session, HCWB traded between $1.50 and $1,866.00, with a volume of 29.78K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, HCW Biologics Inc. (HCWB) moved from $3.60 to $2.88, representing a decline of 20.00% ($0.72).
The stock traded between $2.78 and $2.99 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 206.53 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 3.9%
HCWB is currently trading at $2.88, placing it 3.9% of the way from its 52-week low of $1.50 to its 52-week high of $36.65. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 35 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of HCW Biologics Inc. (HCWB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.